ALPS Group Inc Ordinary Share (NASDAQ:ALPS) Shares to Reverse Split on Monday, November 9th

ALPS Group Inc Ordinary Share (NASDAQ:ALPS)’s stock is going to reverse split on the morning of Monday, November 9th. The 1-5 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Sunday, November 8th.

ALPS Group Inc Ordinary Share Price Performance

Shares of ALPS traded down $0.00 during mid-day trading on Monday, reaching $0.32. The company’s stock had a trading volume of 89,848 shares, compared to its average volume of 65,188. ALPS Group Inc Ordinary Share has a 12-month low of $0.23 and a 12-month high of $1.75. The stock has a market cap of $53.96 million, a PE ratio of 1.25 and a beta of -0.08. The company’s 50 day moving average is $0.37 and its 200 day moving average is $0.56.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of ALPS Group Inc Ordinary Share in a research report on Friday, October 2nd. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

A hedge fund recently raised its position in ALPS Group Inc Ordinary Share stock. SkyView Investment Advisors LLC lifted its stake in shares of ALPS Group Inc Ordinary Share (NASDAQ:ALPS) by 1,000.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 110,000 shares of the company’s stock after purchasing an additional 100,000 shares during the quarter. SkyView Investment Advisors LLC owned about 0.07% of ALPS Group Inc Ordinary Share worth $64,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 27.90% of the company’s stock.

ALPS Group Inc Ordinary Share Company Profile

ALPS Group Inc is a fully integrated platform encompassing biotechnology research, medical, and wellness services specializing in predictive, precision and preventive health management. It aims to provide its clientele with access to DNA and mRNA sequencing, cellular therapy, as well as wellness and anti-aging products and services.